

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)



COMPLETE IF KNOWN

Application Number 09/924,824
 Filing Date August 8, 2001
 First Named Inventor Feng
 Group Art Unit 1653
 Examiner Name
 Attorney Docket Number 20183YCA

RECEIVED

JAN 16 2002

TECH CENTER 1600/2900

Sheet

1

of

3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
P		4,639,456		Trouet et al.	01/27/1987
		5,599,686		DeFeo-Jones et al.	02/04/1997
		5391,723		Priest	02/21/1995
		5,621,002		Bosslet et al.	04/15/1997
		4,870,162		Trouet et al.	09/26/1989
		4,703,107		Monsigny et al.	10/27/1987
		5,024,835		Rao et al.	06/18/1991
		4,719,312		Firestone	01/12/1988
		4,376,765		Trouet et al.	03/15/1983
		4,296,105		Baurain et al.	10/20/1981
✓		5,866,679		DeFeo-Jones et al.	02/02/1999
		5,948,750		Garsky et al.	09/07/1999
P		4,203,898		Cullinan et al.	05/25/1999

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number		
P		PCT	WO 96/00503	Merck & Co., Inc.	01/11/1996
		PCT	WO 98/40738	Sloan Kettering	09/17/1998
		PCT	WO 98/52966	Johns Hopkins University	11/26/1998
		PCT	WO 98/13059	Bristol-Myers Squibb Co.	04/02/1998
		PCT	AU 9532486	La Region Wallonne	03/14/1996
		EPO	0 126 344 A2	Abbott Laboratories	11/28/1984
		PCT	WO 97/12624	Merck & Co., Inc.	04/10/1997
		PCT	WO 97/14416	Merck & Co., Inc.	04/24/1997
		PCT	WO 98/10651	Merck & Co., Inc.	03/19/1998
		PCT	WO 98/18493	Merck & Co., Inc.	05/07/1998

Examiner Signature

Date Considered

07/01/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number 09/924,824
 Filing Date August 8, 2001
 First Named Inventor Feng
 Group Art Unit 1653
 Examiner Name
 Attorney Docket Number 20183YCA

RECEIVED

JAN 16 2002

TECH CENTER 1600/2900

Sheet

2

of

3

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Rao et al., Vinblastin-23-oxy Amino Acid Derivatives: Chemistry, Physicochemical Data, Toxicity, and Antitumor Activities against P388 and L1210 Leukemias, J. Med. Chem., Vol. 28, pp. 1079-1088, 1985.

Seitz et al., Synthesis and Chemical Properties of a Series of Doxorubicin Enaminomalonyl-b-Alanine Derivatives, Tetrahedron Letters, Vol. 36, No. 9, pp. 1413-1416, 1995.

Masquelier et al., Amino Acid and Dipeptide Derivatives of Daunorubicin. 1. Synthesis, Physicochemical Properties, and Lysosomal Digestion, J. Med. Chem., Vol. 23, No. 11, pp. 1166-1170, 1980.

Metzler, The Chemical Reactions of Living Cells, Biochemistry, p. 370, 1977.

Bauraine et al., J. Med. Chem., Vol. 23, No. 11, pp. 1171-1174, 1980.

Trail et al., Science, Vol. 261, pp. 212-215, 1993.

Examiner
SignatureDate
Considered

7/01/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.

TECH CENTER 1600/2000